摘要
目的:探讨B超引导清宫术联合甲氨蝶呤与米非司酮治疗瘢痕妊娠的临床效果。方法:选取2015年3月—2017年3月本院收治的瘢痕妊娠患者90例,按随机数字表法分为观察组与对照组,各45例。对照组采用甲氨蝶呤(50 mg/m2,qd,im)+米非司酮(25 mg,bid,po)治疗,观察组在对照组基础上采用B超引导清宫术治疗,比较两组治疗效果及不良反应。结果:观察组人绒毛膜促性腺激素(HCG)下降至正常水平用时、包块消失用时及住院时间均较对照组短,治疗总有效率高于对照组,不良反应总发生率低于对照组,差异均有统计学意义(P<0.05)。结论:B超引导清宫术联合甲氨蝶呤与米非司酮治疗瘢痕妊娠疗效确切,安全可靠。
Objective: To investigate the clinical efficacy of B-ultrasound-guided uterine curettage combined with methotrexate and mifepristone in treating scar pregnancy. Methods: 90 cases of patients with scar pregnancy admitted to our hospital from March 2015 to March 2017 were selected and divided into observation group and control group according to the random number table method, 45 cases in each group. The patients in the control group were treated with methotrexate(50 mg/m2,qd, im) + mifepristone(25 mg, bid, po). The patients in the observation group were treated by B-ultrasound-guided uterine curettage on the basis of the control group. The efficacy and adverse reactions were compared between the two groups. Results: The time of human chorionic gonadotropin(HCG) decreased to the normal level, the time of mass disappearance and the time of hospitalization were shorter than those in the control group; the total effective rate of the treatment in the observation group was higher than that in the control group and the total incidence of adverse reactions was significantly lower than that in the control group(P<0.05). Conclusion: B-ultrasound-guided uterine curettage combined with methotrexate and mifepristone is effective, safe and reliable in the treatment of scar pregnancy.
出处
《中国执业药师》
CAS
2018年第6期67-69,共3页
China Licensed Pharmacist
关键词
瘢痕妊娠
B超引导清宫术
甲氨蝶呤
米非司酮
安全性
Scar Pregnancy
B-ultrasound Guided Uterine Curettage
Methotrexate
Mifepristone
Safety
